Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive MHLW's Approval for the Treatment of Endometrial Carcinoma
Shots:
- The approval is based on the P-III (KEYNOTE-775/Study 309) trial to evaluate Keytruda (200mg, IV, q3w) + Lenvima (20mg, PO, qd) vs doxorubicin (60mg/m2, IV, q3w) or paclitaxel (80mg/m2, IV, 28-day cycle) in a ratio (1:1) in 827 patients with EC prior treated with 1 Pt-based CT regimen in any setting including neoadjuvant & adjuvant settings
- The results showed improvements in OS & PFS with a 38% reduction in risk of death & 44% in disease progression or death, m-OS (18.3mos. vs 11.4mos.), m-PFS (7.2mos. vs 3.8mos.)
- The combination marks 1st approval in Japan & has received ODD from the MHLW for EC. The companies continue to study the combination across multiple cancer
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com